Abstract
Bullous pemphigoid (BP) is a blistering skin disease characterized by an autoimmune response to 2 hemidesmosomal proteins within the dermal–epidermal junction, designated BP180 and BP230. While BP230 localizes intracellularly and associates with the hemidesmosomal plaque, BP180 is a transmembrane glycoprotein with an extracellular domain. Most BP patients have autoantibodies binding to an immunodominant region of BP180, the noncollagenous 16A domain (NC16A), which is located extracellularly close to the transmembrane domain of the protein. Autoreactive T and B cell responses to BP180 have been found in patients with BP. Passive transfer of antibodies to the murine BP180 ectodomain triggers a blistering skin disease in mice that closely mimics human BP. Lesion formation in this animal model depends upon complement activation, mast cell degranulation and accumulation of neutrophils and eosinophils. Patients’ autoantibodies to BP180 induce dermal–epidermal separation in cryosections of human skin when co-incubated with leukocytes. The loss of cell-matrix adhesion is mediated by proteinases released by granulocytes. The increased knowledge of the pathophysiology of BP should facilitate the development of novel therapeutic strategies for this disease.
Similar content being viewed by others
References
Lever WF (1953) Pemphigus. Medicine 32:2–132
Jordon RE, Beutner EH, Witebsky E, Blumenthal G, Hale WF, Lever WF (1967) Basement membrane antibodies in bullous pemphigoid. JAMA 200:751–756
Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI (1981) Characterization of bullous pemphigoid antigen: A unique basement membrane protein of stratified epithelia. Cell 24:897–903
Mutasim DF, Takahashi Y, Labib RS, Anhalt GJ, Patel HP, Diaz LA (1985) A pool of bullous pemphigoid antigen(s) is intracellular and associated with the basal cell cytoskeleton-hemidesmosome complex. J Invest Dermatol 84:47–53
Labib RS, Anhalt GJ, Patel HP, Mutasim DF, Diaz LA (1986) Molecular heterogeneity of bullous pemphigoid antigens as detected by immunoblotting. J Immunol 136:1231–1235
Borradori L, Sonnenberg A (1999) Structure and function of hemidesmosomes: more than simple adhesion complexes. J Invest Dermatol 112:411–418
Stanley JR, Tanaka T, Mueller S, Klaus-Kovtun V, Roop D (1988) Isolation of complementary DNA for bullous pemphigoid antigen by use of patients’ autoantibodies. J Clin Invest 82:1864–1870
Diaz LA, Ratrie IIIH, Saunders WS, Futamura S, Squiquera HL, Anhalt GJ, Giudice GJ (1990) Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest 86:1088–1094
Giudice GJ, Emery DJ, Diaz LA (1992) Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 99:243–250
Sawamura D, Nomura K, Sugita Y, Mattei M, Chu M, Knowlton R, Uitto J (1990) Bullous pemphigoid antigen (BPAG1): cDNA cloning and mapping of the gene to the short arm of human chromosome 6. Genomics 8:722–726
Li K, Sawamura D, Giudice GJ, Diaz LA, Mattei MG, Chu ML, Uitto J (1991) Genomic organization of collagenous domains and chromosomal assignment of human 180-kD bullous pemphigoid antigen-2, a novel collagen of stratified squamous epithelium. J Biol Chem 266:24064–24069
Tanaka T, Parry DAD, Klaus-Kovtun V, Steinert PM, Stanley JR (1991) Comparison of molecularly cloned bullous pemphigoid antigen to desmoplakin 1 confirms that they define a new family of cell adhesion junction plaque proteins. J Biol Chem 266:12555–12125
Sawamura D, Li K, Chu M-L, Uitto J (1991) Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. J Biol Chem 266:17784–17790
Green KJ, Virata ML, Elgart GW, Stanley JR, Parry DAD (1992) Comperative structural analysis of desmoplakin, bullous pemphigoid antigen and plectin. Members of a new gene family involved in organization of intermediate filaments. Int J Macromol 14:145–153
Giudice GJ, Squiquera HL, Elias PM, Diaz LA (1991) Identification of two collagen domains within the bullous pemphigoid autoantigen, BP180. J Clin Invest 87:734–738
Li K, Tamai K, Tan EML, Uitto J (1993) Cloning of type XVII collagen. J Biol Chem 268:8825–8834
Hirako Y, Usukura J, Nishizawa Y, Owaribe K (1996) Demonstration of the molecular shape of BP180, a 180-kDa bullous pemphigoid antigen and its potential for trimer formation. J Biol Chem 271:13739–13745
Balding SD, Diaz LA, Giudice GJ (1997) A recombinant form of the human BP180 ectodomain forms a collagen-like, homotrimeric complex. Biochemistry 36:8821–8830
Van den Bergh F, Guidice GJ (2003) BP180 (type XVII collagen) and its role in cutaneous biology and disease. Adv Dermatol 19:37–71
Bedane C, McMillan JR, Balding SD, Bernard P, Prost C, Bonnetblanc JM, Diaz LA, Eady RAJ, Giudice GJ (1997) Bullous pemphigoid and cicatrical pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol 108:901–907
Masunaga T, Shimizu H, Yee C, Borradori L, Lazarova Z, Nishikawa T, Yancey KB (1997) The extracellular domain of the lamina densa of BPAG2 localizes to anchoring filaments and its carboxy terminus extends to the lamina densa of normal human epidermal basement membrane. J Invest Dermatol 109:200–206
Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA (1993) Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 151:5742–5750
Zillikens D, Rose PR, Balding SD, Liu Z, Olague-Marchan M, Diaz LA, Giudice GJ (1997a) Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 109:573–579
Guidice GJ, Wilske KC, Anhalt GJ, Fairley JA, Taylor AF, Emery DJ, Hofman RG, Diaz LA (1994) Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol 102:878–881
Perriard J, Jaunin F, Favre B, Büdinger L, Hertl M, Saurat J-H, Borradori L (1999) IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domain of the BP antigen 180. J Invest Dermatol 112:141–147
Di Zenzo G, Grosso F, Terracina M, Mariotti F, De Pita O, Owaribe K, Mastrogiacomo A, Sera F, Borradori L, Zambruno G (2004) Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol 122:103–110
Gaucherand M, Nicolas JF, Paranhos Baccala G, Rouault JP, Reano A, Magaud JP, Thivolet J, Jolivet M, Schmitt D (1995) Major antigenic epitopes of bullous pemphigoid 230 kD antigen map within the C-terminal end of the protein: evidence using a 55 kD recombinant protein. Br J Dermatol 132:190–196
Tanaka M, Hashimoto T, Amagli M, Shimizu N, Ikeguchi N, Tubata T, Hasegawa A, Miki K, Nishikawa T (1991) Characterization of bullous pemphigoid antibodies by use of recombinant bullous pemphigoid antigen proteins. J Invest Dermatol 97:725–728
Rico MJ, Korman NJ, Stanley JR, Tanaka T, Hall RP (1990) IgG antibodies from patients with bullous pemphigoid bind to localized epitopes on synthetic peptides encoded bullous pemphigoid antigen cDNA. J Immunol 145:3728–3733
Ide A, Hashimoto T, Amagai M, Tanaka M, Nishikawa T (1995) Detection of autoantibodies against the bullous pemphigoid and pemphigus antigens by an enzyme-linked immunosorbent assay using the bacterial recombinant proteins. Exp Dermatol 5:112–116
Skaria M, Jaunin F, Hunziker T, Riou S, Schumann H, Bruckner-Tudermann L, Hertl M, Bernard P, Saurat JH, Favre B, Borradori L (2000) IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomain of the COOH–terminus of BP230. J Invest Dermatol 114:998–1004
Kromminga A, Sitaru C, Hagel C, Herzog S, Zillikens D (2004) Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol 111:146–152
Vanderlugt CJ, Miller D (1996) Epitope spreading. Curr Opin Immunol 8:831–836
Zillikens D, Mascara JM, Rose PA, Liu Z, Ewing SM, Caux F, Hoffmann RG, Diaz LA, Giudice GJ (1997b) A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 109:679–683
Schumann H, Baetge J, Tasanen K, Wojnarowska F, Schacke H, Zillikens D, Bruckner-Tuderman L (2000) The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol 156:685–695
Kobayashi M, Amagai M, Kuroda-Kinoshita K, Hashimoto T, Shirakata Y, Hashimoto K, Nishikawa T (2002) BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 30:224–232
Leyendeckers H, Tasanen K, Bruckner-Tudermann L, Zillikens D, Sitaru C, Schmitz J, Hunzelmann N (2003) Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies. J Invest Dermatol 120:372–378
Dopp R, Schmidt E, Shimanovitch I, Leverkus M, Brocker EB, Zillikens D (2000) IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: Serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 42:577–583
Bernard P, Aucouturier P, Denis F, Bonnetblanc JM (1990) Immunoblot analysis of IgG subclasses of circulating antibodies in bullous pemphigoid. Clin Immunol Immunopathol 54:484–494
Laffitte E, Skaria M, Jaunin F, Tamm K, Saurat JH, Favre B, Borradori L (2001) Autoantibodies to the extracellular and intracellular domain of bullous pemphigoid 180, the putative key autoantigen in bullous pemphigoid, belong predominantly to the IgG1 and IgG4 subclasses. Bri J Dermatol 144:760–768
Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DE, Fairley JA, Giudice GJ (1993) A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92:2480–2488
Sitaru C, Schmidt E, Petermann S, Munteanu LS, Brocker EB, Zillikens D (2002) Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 118:664–671
Chorzelski TP, Jablonska S, Beutner EH, Maciejowska E, Jarzabek-Chorzelska M (1976) Herpes gestationis with identical lesions in the newborn. Passive transfer of the disease? Arch Dermatol 112:1129–1131
Katz A, Minto JO, Toole JW, Medwidsky W (1977) Immunopathologic study of herpes gestationis in mother and infant. Arch Dermatol 113:1069–1072
Moncada B, Kettelsen S, Hernandez-Moctezuma JL, Ramirez F (1982) Neonatal pemphigus vulgaris: role of passively transferred pemphigus antibodies. Br J Dermatol 106:465–467
Wasserstrum N, Laros RK (1983) Transplacental transmission of pemphigus. JAMA 249:1480–1482
Hup JM, Bruinsma RA, Boersma ER, de Jong MC (1986) Neonatal pemphigus vulgaris: transplacental transmission of antibodies. Pediatr Dermatol 3:468–472
Ruach M, Ohel G, Rahav D, Samueloff A (1995) Pemphigus vulgaris and pregnancy. Obstet Gynecol Surv 50:755–760
Chowdhury MM, Natarajan S (1998) Neonatal pemphigus vulgaris associated with mild oral pemphigus vulgaris in the mother during pregnancy. Br J Dermatol 139:500–503
Chen SH, Chopra K, Evans TY, Raimer SS, Levy ML, Tyring SK (1999) Herpes gestationis in a mother and child. J Am Acad Dermatol 40:847–849
Büdinger L, Borradori L, Yee C, Eming R, Ferencik S, Grosse-Wilde H, Merk HF, Yancey K, Hertl M (1998) Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 102:2082–2089
Haase C, Büdinger L, Borradori L, Yee C, Merk HF, Yancey K, Hertl M (1998) Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J Invest Dermatol 110:282–286
Sams WM Jr., Gleich GJ (1971) Failure to transfer bullous pemphigoid with serum from patients. Proc Soc Exp Biol Med 136:1027–1031
Anhalt GJ, Diaz LA (1987) Animal models for bullous pemphigoid. Clin Dermatol 5:117–125
Anhalt GJ, Bahn CF, Labib RS, Voorhees JJ, Sugar A, Diaz LA (1981) Pathogenic effects of bullous pemphigoid autoantibodies on rabbit corneal epithelium. J Clin Invest 68:1097–1101
Hall RPI, Murray JC, McCord MM, Rico JM, Streilein RD (1993) Rabbits immunized with a peptide encoded by the 230-kd bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: a potential animal model for bullous pemphigoid. J Invest Dermatol 101:9–14
Ghohestani R (1998) Pathogenic effects of auto-antibodies in skin diseases. In: Nicolas JF, Thivolet J (ed) Immunodermatology, pp 185–200. John Libbey Eurotext, Paris
Korman NJ (1995) In situ-bound antibodies eluted from the skin of patients with bullous pemphigoid are preferentially directed against the 230-kD bullous pemphigoid antigen. J Invest Dermatol 105:824–830
Kiss M, Husz S, Janossy T, Marczinovits I, Molnar J, Korom I, Dobozy A (2005) Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun 24:1–10
Thoma-Uszynski S, Uter W, Schwietzke S, Schuler G, Borradori L, Hertl M (2006) Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol 176:2015–2023
Lin MS, Fu CL, Giudice GJ, Olague-Marchan M, Lazaro AM, Stastny P, Diaz LA (2000) Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J Invest Dermatol 115:955–961
Romagnani S (1992) Human Th1 and Th2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Appl Immunol 98:279–285
Bernard P, Aucouturier P, Denis F, Bonnetblanc JM (1990) Immunoblot analysis of IgG subclass of circulating antibodies in bullous pemphigoid. Clin Immunol Immunopath 54:484–494
D’ Auria L, Cordiali Fei P, Ameglio F (1999) Cytokines and bullous pemphigoid. Eur Cytokine Netw 10:123–134
Gammon WR, Merritt CC, Lewis DM, Sams WM Jr, Wheeler CE Jr, Carlo J (1981) Leukocyte chemotaxis to the dermal–epidermal junction of human skin mediated by pemphigoid antibody and complement: mechanism of cell attachment in the in vitro leukocyte attachment method. J Invest Dermatol 76:514–522
Provost TT, Tomasi TB Jr (1973) Evidence for complement activation via the alternative pathway in skin diseases. Herpes gestationis, systemic lupus erythematosus and bullous pemphigoid. J Clin Invest 52:1779–1787
Jordon RE, Heine KG, Tappeiner G, Bushkell LL, Provost TT (1976) The immunopathology of herpes gestationis. Immunofluorescent studies and characterization of the "HG factor". J Clin Invest 57:1426–1433
Katz SI, Hertz KC, Yaoita H (1976) Herpes gestationis. Immunopathology and characterization of the HG factor. J Clin Invest 57:1434–1441
Kelly SE, Cerio R, Bhogal BS, Black MM (1989) The distribution of IgG subclasses in pemphigoid gestationis: PG factor is an IgG1 autoantibody. J Invest Dermatol 92:695–698
Suzuki M, Harada S, Yaoita Y (1992) Purification of bullous pemphigoid IgG subclasses and their capability for complement fixation. Acta Derm Venerol (Stockh) 72:245–249
Schmidt-Ullrich B, Rule A, Schaumburg-Lever G, Leblanc C (1975) Ultrastructural localization of in vivo-bound complement in bullous pemphigoid. J Invest Dermatol 65:217–219
Jordon RE, Kawana S, Fritz KA (1985) Immunopathologic mechanisms in pemphigus and pemphigoid. J Invest Dermatol 85:72–78
Jordon RE, Day NK, Sam WM Jr, Good RA (1973) The complement system in bullous pemphigoid. Complement and component levels in sera and blister fluids. J Clin Invest 52:1207–1214
Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, Diaz LA (1995) The role of complement in experimental bullous pemphigoid. J Clin Invest 95:1539–1544
Wintroub BU, Mihm MC Jr, Goetzl EJ, Soter NA, Austen KF (1978) Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. N Engl J Med 298:417–421
Dvorak AM, Mihm CM, Osage JE, Kwan TH, Austen KF, Wintroub BU (1982) Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. J Invest Dermatol 78:91–101
Maynard B, Peters MS, Butterfield JH, Leiferman KM (1990) Bullous pemphigoid: eosinophil, neutrophil and mast cell degranulation in lesional tissue. J Invest Dermatol 94:A553
Borrego L, Maynard B, Peterson EA, George T, Iglesias L, Peters MS, Newman W, Gleich GJ, Leiferman KM (1996) Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. Am J Pathol 148:897–909
Chen R, Ning G, Zhao M-L, Fleming MG, Diaz LA, Werb Z, Liu Z (2001) Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 108:1151–1158
Dimson OG, Giudice GJ, Fu CL, Van den Bergh F, Warren SJ, Janson MM, Fairley JA (2003) Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol 120:784–788
Fairley JA, Fu CL, Giudice GJ (2005) Mapping the binding sites of anti-BP180 immunglobulin E autoantibodies in bullous pemphigoid. J Invest Dermatol 125:467–472
Chen R, Fairley JA, Zhao M-L, Giudice ML, Zillikens D, Diaz LA, Liu Z (2002) Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation. J Immunol 169:3987–3992
Muller-Eberhard HJ (1988) Molecular organization of the complement system. Annu Rev Biochem 57:321–347
Galli SJ, Gordon JR, Wershil BK (1991) Cytokine production by mast cells and basophils. Curr Opin Immunol 3:865–872
Galli SJ (1993) New concepts about the mast cell. N Engl J Med 328:257–265
Baba T, Sonozyki H, Seki K, Uchiyama M, Ikesawa Y, Torisu M (1976) An eosinophil chemotactic factor present in blister fluids of bullous pemphigoid patients. J Immunol 116:112–116
Katayama I, Doi T, Nishioka K (1984) High histamine level in the blister fluid of bullous pemphigoid. Arch Dermatol Res 276:126–127
Kawana S, Ueno A, Nishiyama S (1990) Increased levels of immunoreactive leukotriene B4 in blister fluids of bullous pemphigoid patients and effects of a selective 5-lipoxygenase inhibitor on experimental skin lesions. Acta Derm Venerol 70:281–285
Grando SA, Glukhenky BT, Drannik GN, Epshtein EV, Kostromin AP, Korostash AT (1989) Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 125:925–930
Takiguch Y, Kamiyama O, Saito E, Nagao S, Kaneko F, Minagawa T (1989) Cell-mediated immune reaction in the mechanism of blister formation in bullous pemphigoid. Dermatologica 179:137
Endo H, Iwamoto I, Fujita M, Okamoto S, Yoshida S (1992) Increased immunoreactive interleukin-5 levels in blister fluids of bullous pemphigoid. Arch Dermatol Res 284:312–314
Schmidt E, Ambach A, Bastian B, Bröcker E-B, Zillikens D (1996) Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy controls. J Am Acad Dermatol 34:310–312
Schmidt E, Bastian B, Dummer R, Tony HP, Bröcker E-B, Zillikens D (1996) Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res 288:353–357
He S, Peng Q, Walls AF (1997) Potent induction of neutrophil and eosinophil-rich inflitrate in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine. J Immunol 159:6216–6225
Huang C, Friend DS, Qiu WT, Wong GW, Morales G, Hunt J, Stevens RL (1998) Induction of a selective and persistent extravasation of neutrophils into the peritoneal cavity by tryptase mouse mast cell protease 6. J Immunol 160:1910–1919
Compton SJ, Cairns JA, Holgate SH, Walls AF (1998) The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for IL-1β and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. J Immunol 16:1939–1946
Sitaru C, Schmidt E, Petermann S, Munteanu LS, Brocker EB, Zillikens D (2002) Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 118:664–671
Shimanovich I, Mihai S, Oostingh GJ, Ilenchuk TT, Brocker EB, Opdenakker G, Zillikens D, Sitaru C (2004) Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa aquisita and bullous pemphigoid. J Pathol 204:519–527
Liu Z, Giudice GJ, Zhou X, Swartz SJ, Troy JL, Fairley JA, Till GO, Diaz LA (1997) A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 100:1256–1263
Springer TA (1994) Traffic signals fo lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301–314
Liu Z, Shipley JM, Vu TH, Zhou X, Diaz LA, Werb Z, Senior RM (1998) Gelatinase B-deficient mice are resistant to experimental BP. J Exp Med 188:475–482
Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ, Fairley JA, Diaz LA (2000) A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 105:113–123
Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, Senior RM, Werb Z (2000) The serpin α1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102:647–655
Liu Z, Zhao M, Li N, Diaz LA, Mayadas TN (2006) Differential roles for β2 integrins in experimental autoimmune bullous pemphigoid. Blood 107:1063–1069
Yamatomo K, Inoue N, Masuda R, Fujimori A, Saito T, Imajoh-Ohmi S, Shinkai H, Sakiyama H (2002) Cloning of hamster type XVII collagen cDNA, and pathogenesis of anti-type XVII collagen antibody and complement in hamster bullous pemphigoid. J Invset Dermatol 118:485–492
Dubertret L, Bertaux B, Fosse M, Touraine R (1980) Cellular events leading to blister formation in bullous pemphigoid. Br J Dermatol 103:615–624
Iryo K, Tsuda S, Sasai Y (1992) Ultrastructural aspects of infiltrated eosinophils in bullous pemphigoid. J Dermatol 19:393–399
Bushkell LL, Jordon RE (1983) Bullous pemphigoid: a cause of peripheral blood eosinophilia. J Am Acad Dermatol 8:648–651
Wakugawa M, Nakamura K, Hino H, Toyama K, Hattori N, Okochi H, Yamada H, Hira K, Tamaki K, Furue M (2000) Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol 143:112–116
D’Auria L, Pietravalle M, Mastroianni A, Ferraro C, Mussi A, Bonifati C, Giacalone B, Ameglio F (1998) IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity. Arch Dermatol Res 290:25–27
Frezzolini A, Teofoli P, Cianchini G, Barduagni S, Ruffelli M, Ferranti G, Puddu P, Pita OD (2002) Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid. Eur J Dermatol 12:27–31
Czech W, Schaller J, Schopf E, Kapp A (1993) Granulocyte activation in bullous diseases: release of granular proteins in bullous pemphigoid and pemphigus vulgaris. J Am Acad Dermatol 29:210–215
Oikarinen AI, Zone JJ, Ahmed AR, Kiistala U, Uitto J (1983) Demonstration of collagenase and elastase activities in blister fluids from bullous skin diseases. Comparison between dermatitis herpetiformis and bullous pemphigoid. J Invest Dermatol 81:261–266
Welgus HG, Bauer EA, Stricklin GP (1986) Elevated levels of human collagenase inhibitor in blister fluids of diverse etiology. J Invest Dermatol 87:592–596
Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Chernyavsky AL (1989) Cytotoxic proteinases in blister fluid of pemphigus an pemphigoid patients. Int J Tissue React 11:195–201
Grando SA, Glukhenky BT, Drannik GN, Epshtein EV, Kostromin AP, Korostash TA (1989) Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 125:925–930
Gissler HM, Simon MM, Kramer MD (1992) Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid. Br J Dermatol 12:272–277
Jensen PJ, Baird J, Morioka S, Lessin S, Lazarus GS (1988) Epidermal plasminogen activator is abnormal in cutaneous lesions. J Invest Dermatol 90:777–782
Kramer MD, Reinartz J (1993) The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/α2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin. J Clin Invest 92:978–983
Ståhle-Bäckdahl M, Inoue M, Giudice GJ, Parks WC (1994) 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest 93:2022–2030
Niimi Y, Pawankar R, Kawana S (2006) Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol 139:104–113
Verraes S, Hornebeck W, Polette M, Borradori L, Bernard P (2001) Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 117:1091–1096
Liu Z, Li N, Diaz LA, Shipley M, Senior RA, Werb Z (2005) Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 115:879–887
Schmidt E, Wehr B, Tabengwa EM, Reimer S, Brocker EB, Zillikens D (2004) Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes. Clin Exp Immunol 135:497–504
Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13:1382–1397
Bird P, Friedmann PS, Ling N, Bird AG, Thompson RA (1986) Subclass distribution of IgG autoantibodies in bullous pemphigoid. J Invest Dermatol 86:21–25
Bernard P, Aucouturier P, Denis F, Bonnetblanc JM (1990) Immunoblot analysis of IgG subclasses of circulating antibodies in bullous pemphigoid. Clin Immunol Immunopathol 54:489–494
Mihai S, Herrero-Gonzales J, Goodall M, Jefferis R, Savage CO, Zillikens D, Sitaru C (2005) Non-complement fixing IgG4 autoantibodies from bullous pemphigoid patients activate leukocytes and induce blisters in cryosections of human skin. J Invest Dermatol 125:A45
Schmidt E, Reimer S, Kruse N, Jainta S, Brocker EB, Marinkovich MP, Giudice GJ, Zillikens D (2000) Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol 115:842–848
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kasperkiewicz, M., Zillikens, D. The Pathophysiology of Bullous Pemphigoid. Clinic Rev Allerg Immunol 33, 67–77 (2007). https://doi.org/10.1007/s12016-007-0030-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-007-0030-y